0.73
+0.0003(+0.04%)
Currency In USD
Previous Close | 0.73 |
Open | 0.73 |
Day High | 0.73 |
Day Low | 0.7 |
52-Week High | 4.89 |
52-Week Low | 0.6 |
Volume | 27,522 |
Average Volume | 305,818 |
Market Cap | 3.5M |
PE | -0.12 |
EPS | -6.07 |
Moving Average 50 Days | 0.72 |
Moving Average 200 Days | 1.65 |
Change | 0 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of July 04, 2025 at a share price of $0.73. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 5 years ago, it would be worth $0.22 as of July 04, 2025 at a share price of $0.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis
GlobeNewswire Inc.
May 27, 2025 12:30 PM GMT
Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases
GlobeNewswire Inc.
May 06, 2025 12:30 PM GMT
Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit
GlobeNewswire Inc.
May 01, 2025 12:30 PM GMT
Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living w